Skip to content

Efficacy of repetitive transcranial magnetic stimulation in the treatment of postoperative depression in patients with breast cancer: a double-blind, randomized controlled study

Efficacy of repetitive transcranial magnetic stimulation in the treatment of postoperative depression in patients with breast cancer: a double-blind, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097808
Enrollment
Unknown
Registered
2025-02-26
Start date
2025-03-02
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative depression

Interventions

Control group:Repetitive transcranial magnetic stimulation pseudostimulation

Sponsors

The First Hospital Of Jiaxing
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years; 2.American College of Physicians ASA classification ?-?; 3.Patients undergoing elective breast cancer surgery; 4.Preoperative HAMD-17 score >= 7 indicates patients with at least mild depression; 5.Have the ability to cooperate to complete the test plan and correctly understand the evaluation contents; 6.All subjects and their family members gave informed consent to the examination items and signed the informed consent form;

Exclusion criteria

Exclusion criteria: 1.The patient refused to sign the consent form; 2.American College of Physicians ASA classification above ?; 3.Have a history of neuropsychiatric disease or previous neurological or psychiatric disease; 4.Long term use of psychotropic drugs, such as cortisol or antidepressants or anxiolytics; 5.Previous history of epilepsy or currently experiencing an epileptic episode; 6.Craniocerebral or scalp injury, serious cardiovascular and cerebrovascular disease, and infection at the stimulation site; 7.In vivo metal implants (including cardiac pacemakers, intraocular metal implants, history of intracranial metal implantation surgery, cochlea, etc.);

Design outcomes

Primary

MeasureTime frame
Incidence of positive depression screening results 3 days postoperatively;

Secondary

MeasureTime frame
Results of depression screening postoperatively;HAMD-17 score;Frailty score;Sleep quality score;Pain score;Serological indicators;

Countries

China

Contacts

Public ContactHuadong Ni

The First Hospital Of Jiaxing

huadongni@126.com+86 15068386387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026